Abbott India Q4 FY26 Earnings Preview: Healthcare Growth Outlook

Abbott India Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Abbott India was listed on the National Stock Exchange (NSE) on 08-Jan-2010. Abbott India share has its face value of 10 per share, and its NSE symbol is ABBOTINDIA. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Abbott India Q4 Results 2026 Preview

• Abbott India Q4 FY26 revenue is expected to be around Stable Performance, representing a 6-9% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 7-10% YoY.
• EBITDA to rise 7.50%.
• Abbott India is expected to show Stable Performance in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Abbott India Share Performance

• Over the past six months, Abbott India share price has 15% by 6-9% to 27,210.00.
• Moreover, over the past year, the stock has 28% by Up
• Despite this weak short-term performance, Abbott India stock has delivered a financially sound 190% return over the past 5 years.
• As of today, 09-03-2026, the Abbott India share price is trading at 27,210.00 per share.

Key Factors to Watch for Abbott India Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Abbott India

Abbott India manufactures and markets pharmaceutical products across segments like gastroenterology, women’s health, cardiology, and metabolic disorders, catering to healthcare professionals and patients throughout India as a leading player in the country’s healthcare sector.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Abbott India is gear up to announce its Q4 FY26 results. Analysts expect 6-9% revenue growth, a 7-10% rise in PAT, and a 7.50% rise in EBITDA. Abbott India focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Abbott India Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Aakash Exploration Services Gears Up for Q4 Reveal. Check Key Expectations Here

Aarey Drugs & Pharmaceuticals Gears Up for Q4 Reveal. Check Key Expectations Here

Aarnav Fashions Gears Up for Q4 Reveal. Check Key Expectations Here

Aaron Industries Gears Up for Q4 Reveal. Check Key Expectations Here

ABB India Q4 FY26 Results: Analysts Expect Industrial Growth